Sunday, September 25, 2016

8:00 a.m.-8:10 a.m.  Welcome
Sheraton, Metropolitan Ballroom
Margaret Foti, American Association for Cancer Research, Philadelphia, PA
Jill O’Donnell-Tormey, Cancer Research Institute, New York, NY

8:10 a.m.-8:50 a.m.  Keynote Address
Sheraton, Metropolitan Ballroom
Engineering T cell responses to tumors: “Taking the immune system where no responses have gone before”
Philip D. Greenberg, University of Washington School of Medicine and Fred Hutchinson Cancer Research Center, Seattle, WA

8:50 a.m.-12:00 p.m.  Plenary Session 1: Antigens and Vaccines
Sheraton, Metropolitan Ballroom
Session Chairpersons: Cornelis J. M. Melief, Leiden University Medical Center and ISA Pharmaceuticals BV, Leiden, The Netherlands and Robert D. Schreiber, Washington University School of Medicine, St. Louis, MO

8:50 a.m.  Selection of cancer antigens and conditions for success of immunotherapy of cancer involving vaccination
Cornelis J. M. Melief

9:25 a.m.  Therapeutically-active neoantigen-specific cancer vaccines
Robert D. Schreiber

10:00 a.m.  Break

10:30 a.m.  A personalized neoantigen vaccine in patients with high risk melanoma*
Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA

10:45 a.m.  Individualizing cancer medicine by engineered RNA immunotherapies
Ugur Sahin, TRON, Mainz, Germany  (Not designated for CME)

11:15 a.m.  T cell responses to peptide-epitopes of choice can be boosted by immune complexes of circulating anti-tetanus toxoid antibodies*
Sara Mangsbo, Uppsala University, Uppsala, Sweden

11:30 a.m.  T cell recognition and tumor resistance in human cancer
Ton Schumacher, The Netherlands Cancer Institute, Amsterdam, The Netherlands

12:00 p.m.-1:30 p.m.  Lunch
Sheraton, Central Park East and West, Lennox Ballroom, Empire Ballroom (Second Floor) and New York Ballroom (Third Floor)

1:30 p.m.-4:40 p.m.  Session 2: New Checkpoints
Sheraton, Metropolitan Ballroom
Session Chairpersons: Dario A. Vignali, University of Pittsburgh, Pittsburgh, PA, and E. John Wherry, University of Pennsylvania, Philadelphia, PA

1:30 p.m.  Targeting T regs in tumors
Dario A. Vignali

2:10 p.m.  Molecular basis of T cell exhaustion: Insights for immunotherapy
E. John Wherry

2:40 p.m.  HVEM (TNFRSF14) tumor suppressor in immune therapies of follicular lymphoma*
Darin Salloum, Memorial Sloan Kettering Cancer Center, New York, NY

*Proffered presentation
2:55 p.m.  Break

3:25 p.m.  Antitumor T cells: You are what you eat
Susan Kaech, Yale University School of Medicine, New Haven, CT

3:55 p.m.  Identifying and overcoming metabolic checkpoints to antitumor immunity
Greg M. Delgoffe, University of Pittsburgh Cancer Institute, Pittsburgh, PA

4:25 p.m.  CPI-444: A potent and selective inhibitor of A2AR induces antitumor responses alone and in combination with anti-PD-L1 in preclinical and clinical studies*
Stephen Willingham, Corvus Pharmaceuticals, Burlingame, CA

5:00 p.m.-7:30 p.m.
Reception and Poster Session A and Exhibits
Hilton, Americas Halls I and II
A001-A075, Americas Hall I
A075-A148, Americas Hall II

The following topics will be presented:
Antigens and Vaccines
Microbiota
New Checkpoints
Tumor Microenvironment
Other Topics

Monday, September 26, 2016

8:00 a.m.-8:40 a.m.
William B. Coley Lecture
Sheraton, Metropolitan Ballroom

The commensal microbiota as instructors and arbiters of homeostatic and pathogenic immune responses
Dan R. Littman, NYU School of Medicine, New York, NY

8:40 a.m.-12:20 p.m.
Session 3: Tumor Microenvironment
Sheraton, Metropolitan Ballroom

Session Chairpersons: Wolf Hervé Fridman, Cordeliers Research Center (INSERM), Paris, France, and Shannon J. Turley, Genentech, Inc., South San Francisco, CA

8:40 a.m.  Tumor microenvironments: Prognostic and theranostic impacts
Wolf Hervé Fridman

9:20 a.m.  Emerging insights into stromal cell function in immune homeostasis and inflammation
Shannon J. Turley

9:50 a.m.  Targeting regulatory T cells for cancer immunotherapy
Shimon Sakaguchi, Osaka University, Osaka, Japan

10:20 a.m. Break

10:50 a.m.  Immune suppressive and immune stimulating monocytes in cancer
Vincenzo Bronte, University of Verona, Verona, Italy

11:20 a.m.  Peripheral blood immune profiling of anti-PD-1 therapy in human melanoma reveals a link between T cell re-invigoration and tumor burden that predicts response*
Alexander Huang, University of Pennsylvania, Philadelphia, PA

11:35 a.m.  Overcoming intratumor T-cell exclusion by modulation of lactate metabolism to improve immune checkpoint therapies in aggressive breast cancer*
Taha Merghoub, Memorial Sloan Kettering Cancer Center, New York, NY

11:50 a.m.  Targeting focal adhesion kinase to awaken responses to immunotherapy in pancreatic cancer
David G. DeNardo, Washington University School of Medicine, St. Louis, MO

*Proffered presentation
CONFERENCE PROGRAM AND SCHEDULE

12:20 p.m.-1:50 p.m.
Lunch
Sheraton, Central Park East and West, Lennox Ballroom, Empire Ballroom (Second Floor) and New York Ballroom (Third Floor)

1:50 p.m.-4:55 p.m.
Session 4: Microbiota
Sheraton, Metropolitan Ballroom

Session Chairpersons: Guido Kroemer, Gustave Roussy, Paris Decartes University, INSERM, AP-HP, Paris, France, and Giorgio Trinchieri, National Cancer Institute, Bethesda, MD

1:50 p.m.  Microbiota and cancer immunosurveillance: An introduction
Guido Kroemer

2:10 p.m.  Cancer as a disease of the symbiont/metaorganism
Giorgio Trinchieri

2:40 p.m.  Gut microbiota controls immune responses during cancer therapy
Laurence Zitvogel, Institut Gustave Roussy, Villejuif, France

3:10 p.m.  Break

3:40 p.m.  Bioorthogonal chemical labeling of specific immunomodulatory surface molecules in live commensals*
Jason Hudak, Harvard Medical School, Boston, MA

3:55 p.m.  Gut microbiota-host immunomodulatory interactions
Naama Geva-Zatorsky, Harvard Medical School, Boston, MA

4:25 p.m.  Myeloid cells contribution to tumor development and response to treatment
Miriam Merad, Icahn School of Medicine at Mount Sinai, New York, NY

5:15 p.m.-7:45 p.m.
Reception and Poster Session B and Exhibits
Hilton, Americas Halls I and II
B001-B072, Americas Hall I
B073-B145, Americas Hall II

The following topics will be presented:

Clinical Trials of Cancer Immunotherapies
Emerging Technologies
Mechanistic Merging of Treatment Modalities
New Agents and Their Mode of Action in Animals and Humans
Non-Checkpoint Immunotherapies
Trials in Progress
Other Topics

Tuesday, September 27, 2016

8:00 a.m.-11:40 a.m.
Session 5: Mechanistic Merging of Treatment Modalities
Sheraton, Metropolitan Ballroom

Session Chairpersons: Ira Mellman, Genentech, Inc., South San Francisco, CA, and Drew M. Pardoll, Johns Hopkins Medicine, Baltimore, MD

8:00 a.m.  Mechanism-based combination strategies in cancer immunotherapy
Ira Mellman

8:40 a.m.  How much cancer can we cure with the immune system?
Drew M. Pardoll

9:10 a.m.  Rational combinations of targeted and immunotherapies
Patrick Hwu, The University of Texas MD Anderson Cancer Center, Houston, TX

9:40 a.m.  Break

*Proffered presentation
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:10 a.m.</td>
<td>Is the right flavor of inflammation the key to successful therapy?</td>
<td>Romina Goldszmid, National Cancer Institute, NIH, Bethesda, MD</td>
</tr>
<tr>
<td>10:40 a.m.</td>
<td>Phase 2 study to evaluate the clinical efficacy and safety of MEDI4736 (durvalumab) in patients with glioblastoma (GBM): Results for cohort B (durvalumab monotherapy), bevacizumab-naïve patients with recurrent GBM</td>
<td>David A. Reardon, Dana-Farber Cancer Institute, Boston, MA</td>
</tr>
<tr>
<td>11:10 a.m.</td>
<td>Identifying the epigenetic code of tumor-specific CD8 T cell dysfunction and therapeutic reprogramming*</td>
<td>Mary Philip, Memorial Sloan Kettering Cancer Center, New York, NY</td>
</tr>
<tr>
<td>11:25 a.m.</td>
<td>Antitumor activity and immune correlates of PEGylated human IL-10 (AM0010) alone or in combination with anti-PD-1*</td>
<td>Martin Oft, ARMO, Palo Alto, CA</td>
</tr>
<tr>
<td>11:40 a.m.-1:10 p.m.</td>
<td>Lunch</td>
<td>Sherton, Central Park East and West, Lennox Ballroom, Empire Ballroom (Second Floor) and New York Ballroom (Third Floor)</td>
</tr>
<tr>
<td>1:10 p.m.-5:00 p.m.</td>
<td>Session 6: Non-Checkpoint Immunotherapies</td>
<td>Sheraton, Metropolitan Ballroom</td>
</tr>
<tr>
<td></td>
<td>Session Chairpersons: Glenn Dranoff, Novartis Institutes for BioMedical Research, Cambridge, MA, and Axel Hoos, GlaxoSmithKline Pharmaceuticals, Collegeville, PA</td>
<td></td>
</tr>
<tr>
<td>1:10 p.m.</td>
<td>Introduction</td>
<td>Axel Hoos</td>
</tr>
<tr>
<td>1:30 p.m.</td>
<td>Immune mobilizing TCR therapies against cancer (ImmTAC): A novel class of antigen specific tumor immunotherapy (Not designated for CME)</td>
<td>Christina M. Coughlin, Immunocore Limited, Philadelphia, PA</td>
</tr>
<tr>
<td>2:00 p.m.</td>
<td>Targeting inducible T cell co-stimulator (ICOS) promotes effector T cell function and anti-tumor response</td>
<td>Patrick A. Mayes, GlaxoSmithKline Pharmaceuticals, Collegeville, PA</td>
</tr>
<tr>
<td>2:30 p.m.</td>
<td>Small-molecule inhibitors of CD73 promote activation of human CD8+ T cells and have profound effects on tumor growth and immune parameters in experimental tumors*</td>
<td>Juan C. Jaen, Arcus Biosciences, Inc., Hayward, CA</td>
</tr>
<tr>
<td>2:45 p.m.</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>3:15 p.m.</td>
<td>Microenvironmental regulation of anti-tumor immune responses: A lesson from fibroblastic cells</td>
<td>Viviana Cremasco, Novartis Institutes for BioMedical Research, Cambridge, MA</td>
</tr>
<tr>
<td>3:45 p.m.</td>
<td>Macrophage repolarization therapy in metastatic colorectal cancer: CCR5 inhibition*</td>
<td>Niels Halama, National Center for Tumor Diseases, Heidelberg, Germany</td>
</tr>
<tr>
<td>4:00 p.m.</td>
<td>New frontiers in oncolytic virus therapy (Not designated for CME)</td>
<td>David M. Reese, Amgen, Thousand Oaks, CA</td>
</tr>
<tr>
<td>4:30 p.m.</td>
<td>Synergistic innate and adaptive integrin-targeted immunotherapy</td>
<td>K. Dane Wittrup, Massachusetts Institute of Technology, Cambridge, MA</td>
</tr>
</tbody>
</table>

*Proffered presentation
Wednesday, September 28, 2016

8:00 a.m.-10:40 a.m.
Session 7: New Agents and Their Mode of Action in Animals and Humans
Sheraton, Metropolitan Ballroom

Session Chairpersons: Elizabeth M. Jaffee, Johns Hopkins Medicine, Baltimore, MD and Mark J. Smyth, QIMR Berghofer Institute, Melbourne, Australia

8:00 a.m. Combinatorial immunotherapies with the potential to reverse the carcinogenesis process
Elizabeth M. Jaffee

8:30 a.m. Novel natural killer cell targets for cancer immunotherapy
Mark J. Smyth

9:00 a.m. Targeting FSTL1 augments therapeutic activities of immune checkpoint inhibitors*
Chie Kudo-Saito, National Cancer Center, Tokyo, Japan

9:15 a.m. The anti-CD47 antibody Hu5F9-G4 is a novel immune checkpoint inhibitor with synergistic efficacy in combination with clinically active cancer targeting antibodies*
Mark P. Chao, Forty Seven, Inc, Palo Alto, CA

9:30 a.m. Cancer epigenetic and metabolic mechanisms controlling immunotherapy and chemotherapy
Weiping Zou, University of Michigan School of Medicine, Ann Arbor, MI

10:00 a.m. Manipulating inflammation to raise cancer immunogenicity
Santiago Zelenay, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, United Kingdom

10:30 a.m. Break

11:00 a.m.-1:10 p.m.
Session 8: Emerging Technologies
Sheraton, Metropolitan Ballroom

Session Chairperson: Matthew F. Krummel, University of California, San Francisco, CA

11:00 a.m. Visualizing tumor immune interaction in real time
Matthew F. Krummel

11:40 a.m. Technologies for personalizing cancer immunotherapies
James R. Heath, California Institute of Technology, Pasadena, CA

12:10 p.m. Tumor neoepitope selection for biomarker discovery and therapeutic vaccination
Jeffrey E. Hammerbacher, Icahn School of Medicine at Mount Sinai, New York, NY

12:40 p.m. Automatic identification of cell niches and immune interactions important for clinical outcomes using multiparameter imaging and deep neural networks*
Salil S. Bhate, Stanford University, Stanford, CA

12:55 p.m. Engineering phagocytic signaling *
Adam Williamson, University of California, San Francisco, CA

1:10 p.m.-1:20 p.m.
Closing Remarks
Axel Hoos, GlaxoSmithKline Pharmaceuticals, Collegeville, PA

1:20 p.m.
Meeting Ends

*Proffered presentation